Table 2 Summary of cases characteristics
From: Multisystem Inflammatory Syndrome (MIS) following SARS-CoV-2 vaccinations; a systematic review
Variable | Total (n = 37) |
|---|---|
Age (years) Median (Range) | 18 (1–67) |
Gender M: F | 3.1:1 |
Country n (%) | |
 Canada | 1 (2.7) |
 Germany | 1 (2.7) |
 India | 3 (8.1) |
 Italy | 1 (2.7) |
 Japan | 2 (5.4) |
 Korea | 1 (2.7) |
 New Zealand | 1 (2.7) |
 Qatar | 1 (2.7) |
 South Korea | 1 (2.7) |
 Turkey | 1 (2.7) |
 United Arab Emirates | 1 (2.7) |
 United Kingdom | 2 (5.4) |
 United States | 10 (27.0) |
 France | 9 (24.3) |
 Romania | 1 (2.7) |
 Denmark | 1 (2.7) |
Age Group n (%) | |
 Paediatric | 19 (51.4) |
 Adult | 18 (48.6) |
Chronic Disease n (%) | |
 Haemoglobin SS disease | 1 (2.7) |
 Methicillin sensitive staphylococcal septic arthritis | 1 (2.7) |
 Lyme disease | 1 (2.7) |
 Hypertension | 2 (5.4) |
 Diabetes | 2 (5.4) |
 Hypoxic ischemic encephalopathy | 1 (2.7) |
 Epilepsy | 1 (2.7) |
 Asthma | 4 (10.8) |
 Depression | 1 (2.7) |
 Hyperlipidaemia | 1 (2.7) |
 Osteochondritis | 1 (2.7) |
 Leukaemia | 1 (2.7) |